GenoMed says Healthchip may predict six common cancers

By Lisa Kerner

Erie, Pa., March 8 - GenoMed said it has developed Healthchip, a genomic test for predicting six common cancers: breast, colon, lung, ovarian, pancreatic and prostate.

Healthchip, consisting of several hundred single nucleotide polymorphisms (SNPs), currently identifies patients 85% of the time, according to a company news release.

GenoMed said several more years of tests will be required before Healthchip could be approved by the Food and Drug Administration.

The Healthchip is only available on a research basis and costs $1,000 for research participants due to genotyping costs, the company said.

"Screening for the six cancers is currently possible in Caucasians only," chief executive officer and chief medical officer Dr. David Moskowitz said in the release.

"We would like to extend this work to African American, Asian and Hispanic patients. We would also like to extend our Healthchip to include more than the top six solid cancers in adults, as well as cancers in children."

St. Louis-based GenoMed finds disease-causing genes to devise new treatment strategies. The Healthchip is available on a research basis only.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.